Abstract
Alzheimers disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.
Keywords: Glycosphingolipids, ganglioside, presenilin, neurotrophin, Trk, lipid rafts, cholesterol, familial Alzheimer's disease
CNS & Neurological Disorders - Drug Targets
Title: Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
Volume: 5 Issue: 4
Author(s): Tatsuro Mutoh, Yoshio Hirabayashi, Takateru Mihara, Madoka Ueda, Hiroshi Koga, Akihiro Ueda, Takako Kokura and Hiroko Yamamoto
Affiliation:
Keywords: Glycosphingolipids, ganglioside, presenilin, neurotrophin, Trk, lipid rafts, cholesterol, familial Alzheimer's disease
Abstract: Alzheimers disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.
Export Options
About this article
Cite this article as:
Mutoh Tatsuro, Hirabayashi Yoshio, Mihara Takateru, Ueda Madoka, Koga Hiroshi, Ueda Akihiro, Kokura Takako and Yamamoto Hiroko, Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2006; 5 (4) . https://dx.doi.org/10.2174/187152706777950710
DOI https://dx.doi.org/10.2174/187152706777950710 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Computational Models for 5αR Inhibitors for Treatment of Prostate Cancer: Review of Previous Works and Screening of Natural Inhibitors of 5αR2
Current Computer-Aided Drug Design Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Editorial (Hot Topic: Neurodegeneration with Brain Iron Accumulation)
Current Drug Targets Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Dopamine: Agonists and Neurodegenerative Disorders
Current Drug Targets Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Nano Clinoptilolite: Highly Efficient Catalyst for the Synthesis of Chromene Derivatives Under Solvent-Free Conditions
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Food, Nutrition & Agriculture Determination of Spatial and Temporal Distribution of Microglia by 230nm-High-Resolution, High-Throughput Automated Analysis Reveals Different Amyloid Plaque Populations in an APP/PS1 Mouse Model of Alzheimers Disease
Current Alzheimer Research Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Anti-Inflammatory Agents in Parkinsons Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chelating Agents for Neurodegenerative Diseases
Current Medicinal Chemistry Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity
Current Protein & Peptide Science